Effect of tumor budding and tumor infiltrating lymphocytes on prognosis of colorectal mucinous adenocancers

Mucinous adenocarcinoma (MAC) has a worse prognosis than do classical adenocarcinoma. Increased tumor budding (TB) and lower number of tumor infiltrating lymphocytes (TIL) negatively affect prognosis in classical adenocarcinoma. In this study, we investigated whether TB and TIL values influenced prognosis in patients with MAC. Forty-five patients diagnosed with MAC between 2011 and 2015 were included in the study. TB and TIL values of the patients were re-evaluated. In assessing TIL, lymphocytes that infiltrated the stroma and tumor were evaluated separately. The effects of these findings on the prognostic parameters and the disease-free survival (DFS) and overall survival (OS) were evaluated. The mean follow-up period was 26.07 months (min: 1 max: 82, SD:24.86), OS 28.04 months (min: 1 max: 82 SD:24.81). The results between TB and OS (p = 0.066) and DFS (p = 0.205) were not significant. The relationship between sTIL and OS (p = 0.367) and DFS (p = 0.949) was not significant. The relationship between iTIL and OS (p = 0.502) and DFS (p = 0.870) was not significant. The only significant difference between clinicopathological parameters and TB, sTIL, and iTIL was between grade and TB (p = 0.016). In terms of clinicopathologic parameters, stage with OS (p = 0.008) and DFS (0.016), lymph node metastasis with OS (p = 0.010) and DFS (0.008), LVI (lymph vascular invasion) with OS (p = 0.034) and DFS (p = 0.015), PNI (perineural invasion) and DFS (p = 0.007) was significant. In this study, the effect of TB and TIL on the prognosis of MAC was investigated. We found that these data did not correlate with the prognosis of the tumor and the prognostic parameters (LVI, PNI, lymph node metastasis, stage) in the staging system remained as the gold standard for predicting prognosis.

___

Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.

Hamilton SR, Bosman FT, Boffeta P, Ilyas m, Morreau H. Carcinoma of the colon and rectum. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: IARC; 2010. p. 134-47.

Parham D. COLLOID CARCINOMA. Ann Surg. 1923;77: 90–105.

Song BR, Xiao CC, Wu ZK. Predictors of Lymph Node Metastasis and Prognosis in pT1 Colorectal Cancer Patients with Signet-Ring Cell and Mucinous Adenocarcinomas. Cell Physiol Biochem. 2017;41:1753-65.

Pozos-Ochoa LI, Lino-Silva LS, León-Takahashi AM, et al. Prognosis of Signet Ring Cell Carcinoma of the Colon and Rectum and their Distinction of Mucinous Adenocarcinoma with Signet Ring Cells. A Comparative Study. Pathol Oncol Res. 2018;24:609-16.

Graham RP, Vierkant RA, Tillmans LS, et al. Tumor Budding in Colorectal Carcinoma: Confirmation of Prognostic Significance and Histologic Cutoff in a Population-based Cohort. Am J Surg Pathol. 2015;39:1340-6.

Petrelli F, Pezzica E, Cabiddu M, et al. Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis. J Gastrointest Cancer. 2015;46:212-8.

Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30:1299-311.

Salgado R, Denkert C, Demaria S, et al. The evaluation of tumorinfiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259–71.

10. Park JH, Roxburgh CS, McMillan DC. Comment on ‘Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and metaanalysis’. Br J Cancer. 2014;111:2372.

11. Jas1986 Jass JR. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol. 1986;39:585–9.

12. Millar EK, Beretov J, Sarris M, Lee CS. Mucinous differentiation in colonic adenocarcinoma is associated with a reduction in tumour-infiltrating lymphocytes. Eur J Surg Oncol. 2001;27:273-7.

13. Swisher SK, Wu Y, Castaneda CA, et al. Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. Ann Surg Oncol. 2016 Mar 10.

14. Okuyama T, Oya M, Yamaguchi M. Budding (sprouting) as a useful prognostic marker in colorectal mucinous carcinoma. Jpn J Clin Oncol. 2002;32:412-6.

15. Kakar S, Shi C, Berho EM, et al. Protocol for the Examination of Specimens From Patients With Primary Carcinoma of the Colon and Rectum. Includes pTNM requirements from the 8th Edition, AJCC Staging Manual College of American Pathologists Consensus 2017

16. Ha SS, Choi HJ, Park KJ, et al. Intensity of tumor budding as an index for the malignant potential in invasive rectal carcinoma. Cancer Res Treat. 2005 Jun;37(3):177-82. doi: 10.4143/crt.2005.37.3.177. Epub 2005 Jun 30. PubMed PMID: 19956500; PubMed Central PMCID: PMC2785407.Ha 2005

17. Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer--ready for diagnostic practice? Hum Pathol. 2016 ;47:4-19.

18. Weedon D, LeBoit G, Burg G and Sarasin A: Pathology and Genetics of Tumours of the Skin. IARC Press, ISBN 92 83 224140

19. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol. 2005;25:1544 50.

20. Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor infiltrating lymphocytes (TILs) in triple negative breast cancers (TNBC) from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959 66.

21. Jakubowska K, Kisielewski W, Kańczuga-Koda L, et al. Stromal and intraepithelial tumor-infiltrating lymphocytes in colorectal carcinoma. Oncol Lett. 2017;14:6421-32.

22. Weiss JM, Pfau PR, O’Connor ES, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data. J Clin Oncol. 2011;29:4401-9.

23. Benedix F, Kube R, Meyer F, et al. Colon/Rectum Carcinomas (Primary Tumor) Study Group. Comparison of 17,641 patients with right- and leftsided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010;53:57-64.

24. Gervaz P, Bouzourene H, Cerottini JP, Chaubert P, Benhattar J, Secic M, Wexner S, Givel JC, Belin B. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum. 2001;44:364-72.

25. Hosseini S, Bananzadeh AM, Salek R, et al. Prognostic Significance of Mucinous Histologic Subtype on Oncologic Outcomes in Patients With Colorectal Cancer. Ann Coloproctol. 2017;33:57-63.

26. Meguid RA, Slidell MB, Wolfgang CL, et al. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol. 2008;15:2388-94.

27. Derwinger K, Gustavsson B. Variations in demography and prognosis by colon cancer location. Anticancer Res. 2011;31:2347-50.

28. Qiu MZ, Pan WT, Lin JZ, et al. Comparison of survival between right-sided and left-sided colon cancer in different situations. Cancer Med. 2018;7:114150.

29. Lim SB, Yu CS, Jang SJ, et al. Prognostic significance of lymphovascular invasion in sporadic colorectal cancer. Dis Colon Rectum. 2010;53:377-84.

30. Hu D, Cao B, Li S, Li P, Zhang S. Incidence, risk factors, and a predictive model for lymph node metastasis of submucosal (T1) colon cancer: a population-based study. J Dig Dis. 2019.

31. Ozturk MA, Dane F, Karagoz S, et al. Is perineural invasion (PN) a determinant of disease free survival in early stage colorectal cancer? Hepatogastroenterology. 2015;62:59-64.